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138Superﬁcial femoral artery nitinol stent in a patient
with nickel allergy
Prasad Jetty, MD, FRCSC, MSc,a Srinidhi Jayaram, MD,a John Veinot, MD,b and Melanie Pratt, MD,c,d
Ottawa, Ontario, Canada
We present a case of a patient who developed a systemic allergic reaction following placement of a nitnol stent in the
superﬁcial femoral artery for claudication symptoms. Shortly after, he was tested for contact dermatitis and found to have
a severe reaction to nickel. His symptoms of severe itch and generalized rash resolved within days following stent
explantation and reconstruction with a vein graft. The epidemiology and clinical signiﬁcance of nickel allergy and the
concomitant use of nickel-alloy stents are discussed. (J Vasc Surg 2013;58:1388-90.)There has been a rapid rise in the number of endovas-
cular procedures being performed for peripheral vascular
disease, and with it, the use of self-expandable nitinol stents
in the superﬁcial femoral artery. It is also well documented
that worldwide, the most common allergen in patients
assessed for contact allergy, is nickel, the predominant
component of nitinol.1 The use of nitinol stents in patients
with nickel allergy undergoing superﬁcial femoral artery
angioplasty has not been well studied in the literature.
CASE REPORT
An active 55-year-old machinist presented with disabling right
calf claudication. After a 6-month trial of risk factor management
and exercise, he underwent a subintimal angioplasty of a complete
occlusion of the superﬁcial femoral artery and placement of a 7-
mm  15-cm nitinol stent. Clopidogrel therapy was initiated on
discharge the same day. Following the procedure, the patient
had complete resolution of his claudication in the right leg with
an ankle-brachial index of 1.1. The patient had no history of any
drug or metal allergies prior to the procedure.
Two weeks following the procedure, he presented to a derma-
tologist with generalized severe pruritus and an eczematous
dermatitis worse on the right leg (Fig 1). Patch testing (according
to North American Contact Dermatitis group guidelines2)
revealed a severe reaction to nickel sulfate only. A biopsy of the
rash revealed spongiotic dermatitis with a moderate superﬁcial
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8eosinophils. Assuming that the cause of his dermatitis was related
to occupational exposure to nickel, he was put on corticosteroid
therapy (topical betamethasone 0.1%, followed by prednisone 40
mg orally, tapered over 6 weeks), and repositioned to a different
job location with no potential for metal exposure. Despite this,
the patient had persistence of his severe pruritic eczematous
dermatitis on his lower extremities, and developed localized pain
on deep palpation in his midthigh in the area of the superﬁcial
femoral artery stent. In addition, the patient complained of short-
ness of breath and fatigue.
After 8 months, he eventually returned to the vascular
surgeon, and the potential for an allergic reaction to the stent
was entertained. His blood work was normal, and a computed
tomography angiogram revealed a patent stent without any major
surrounding inﬂammatory reaction. After consultation with an
expert in contact dermatitis, and with the insistence of the patient,
the decision was made to explant the nitinol stent. This was per-
formed in the operating room, through a medial thigh incision
and complete mobilization of the distal superﬁcial femoral artery.
The segment of artery containing the stent was completely
resected (w15 cm). Reconstruction was performed with an inter-
position reversed saphenous vein graft. We noted dense scar tissue
around the artery for the entire length of the stent but no acute
inﬂammatory reaction. On postoperative day 1, the patient had
almost complete resolution of his severe itch, and by 1 month he
had resolution of his dermatitis and fatigue (Fig 2).
Pathological analysis was performed, with the stented artery
formalin ﬁxed and decalciﬁed. The stent was deployed within the
arterial wall (subintimal plane) displacing the native lumen and
its surrounding media with obliteration of the true lumen. There
was severe intimal ﬁbroplasia within the neolumen, with a mild
chronic inﬂammatory response, chieﬂy plasma cells, macrophages,
and lymphocytes. Giant cells and eosinophils were not prominent
(Fig 3). X-ray of the specimen revealed a stent fracture. Following
the procedure, the patient had complete resolution of his claudica-
tion in the right leg with an ankle-brachial index of 1.1. The
patient remains asymptomatic with respect to his claudication
symptoms and without recurrence of his severe pruritic rash 2 years
following stent explantation.
DISCUSSION
Advancements in endovascular techniques have re-
sulted in an increasing use of self-expandable nitinol alloy
Fig 1. Pruritic and an eczematous dermatitis worse on the right
leg 1 month prior to stent explantation.
Fig 2. Resolution of dermatitis 1 month following stent explan-
tation and reconstruction of the superﬁcial femoral artery with an
interposition vein graft.
Fig 3. Low power microscopy with hematoxylin and eosin
(H&E) stain of cross-section of explanted arterial segment of
superﬁcial femoral artery. A, Native artery compressed; L, neo-
lumen with intimal hyperplasia inside of subintimally-deployed
stent. Arrows are pointing to the stent struts.
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ischemia. To our knowledge, despite an increasing inci-
dence of nickel sensitivity in North America,3 this is the
ﬁrst report documenting a reaction to a peripheral nitinol
stent as a result of a systemic contact dermatitis from nickel
allergy.
The predominant component of the nitinol is nickel
(54.5%-57% by weight).4 Nickel allergy is one of the
most common allergies and causes of dermatitis in the
world, with a reported incidence of 8% to 15% in the
general population.3,5 History often suggests previous
pruritic rashes or dermatitis in the area of contact with
metal jewelry, or previous occupational exposure.6-8 The
“nickel itch” is an early symptom and is often severe and
continuous as long as the allergen is present.1,6,8 Nickel
dermatitis is classiﬁed into primary (an eczematous reactionin the area of skin that is in contact with nickel) and
secondary (a more widespread dermatitis as a result of
exposures such as ingestion, transfusion, inhalation, and
implantation of metal medical devices). Secondary erup-
tions are considered as systemic contact dermatitis and
are typically widespread and symmetrically distributed.
Despite the incidence of nickel allergy in the general
population, a literature review of the PubMed, Medline,
Embase, and Cochrane databases did not identify any
previous studies or reports of reactions during the use of
superﬁcial femoral artery nitinol stents in patients with
nickel allergy. We postulate that this may be a result of
a few factors including: (1) the amount of free nickel
allergen from nitinol stents may be too low in most individ-
uals to surmount a clinically signiﬁcant reaction; (2) the
intravascular location of the nickel exposure may dilute
the severity of the reaction compared with a localized
dermal exposure; and (3) patients who develop systemic
contact dermatitis reactions postnitinol stenting are
possibly unrecognized.
Gimenez-Arnau et al9 reported generalized pruritic
dermatitis in a patient after endovascular repair of an
abdominal aortic aneurysm with an early aortic stent graft
made of nitinol in 1999. The patient complained of persis-
tent pruritus and eczema with excoriated papules approxi-
mately 3 weeks post aortic stent insertion. The graft was
not removed, and her symptoms were managed with
anti-histamine medications and topical steroids.
Khan et al10 reported the occlusion of a biliary stent
place for biliary stricture attributed to nickel allergy. The
patient had a previous diagnosis of nickel dermatitis clini-
cally but not conﬁrmed by patch testing. After the diag-
nosis of recurrent biliary obstruction, the stent was
JOURNAL OF VASCULAR SURGERY
1390 Jetty et al November 2013removed surgically. Histological evaluation revealed eosin-
ophils and lymphocytes in an inﬂammatory inﬁltrate.
Several reports have hypothesized that the delayed type
IV hypersensitivity reaction in nickel-allergic patients may
be a triggering or exacerbating factor to the inﬂammatory
process involved in coronary in-stent restenosis, and some
have contrarily suggested no clinical signiﬁcance of nickel
allergy in this setting.11-19 A deﬁnitive association between
in-stent restenosis and nickel allergy has yet to be
conﬁrmed. Coronary stents are smaller stainless steel or
cobalt chromium alloy stents, and thus the proportion of
nickel and the overall nickel burden is signiﬁcantly lower
when compared with the self-expandable nitinol stents
used in peripheral vascular disease (5%-10% vs 55%, respec-
tively).12-14
Although our patient had a deﬁnitive diagnosis of
nickel allergy, we did not have any objective radiological,
laboratory, or pathologic ﬁndings of a systemic reaction
to the nitinol stent. As he continued to worsen, despite
steroid therapy and removal of occupational exposure, we
assumed he had continued exposure to nickel from his
stent. Removal of the stent and reconstruction with
a vein graft led to an immediate improvement in his symp-
toms of itch and rash, which was appreciated on postoper-
ative day 1. We suspect the stent fracture also contributed
to the systemic nickel contact dermatitis reaction in our
patient. The histological evaluation of the stent and
surrounding artery showed a signiﬁcant ﬁbro proliferative
reaction, and, although there was no signiﬁcant eosino-
philia, the histological sections illustrated a marked activa-
tion of inﬂammatory cells. Having said that, although
there may be eosinophils in the dermal inﬁltrate, this is
often not present in the chronic phase.
This case report illustrates the potential of a systemic
reaction in the setting of nickel allergy following placement
of these large nitinol stents used in peripheral vascular
disease. The clinical signiﬁcance of known nickel allergy
in patients requiring peripheral vascular stents is unknown
but likely dependent on the degree of severity of the
previous allergic reaction.20 The affect of nickel allergy
on stent patency is also unknown and may be dependent
on bioavailability of nickel, potentially increased in the
setting of metal wear-and-tear and stent fracture. Further
studies are required to test these hypotheses. Although,
there is little literature on reactions to nitinol stents, one
should consider alternatives to the use of nitinol stents in
patients with a history of severe reaction to nickel-
containing products.REFERENCES
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